Page 1249 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1235

Plazomicin, 832 Polygenic effects, CYP2C9 and VKORC1, with loop or thiazide diuretics, 269
Plerixafor, 604, 606t 80t, 85–86 with proximal tubule diuretics, 269
Plexus of Auerbach, 92 Polymerase inhibitors, 889 drug interactions of, 1170t–1171t
Plexus of Meissner, 92 Polymer fume fever, 1016 preparations available, 274t
Plicamycin, 788–789 Polymorphic ventricular tachycardia, 233f, Potassium wasting, from carbonic
Pneumococcal vaccines 234b, 237f anhydrase inhibitors, 261
pneumococcal conjugate, 1177t Polymorphism, 75t Potency
pneumococcal polysaccharide, 1177t Polymyxin B sulfate, 1070–1071 definition of, 36
Pneumocystis jiroveci, 925 Polymyxins, 896 pharmacologic, 36, 36f
Pneumocystosis, pentamidine for, 931, 933 Polypharmacy, 177b Povidone-iodine, 899
Pneumonia, community-acquired, 795, Polyvinyl pyrrolidone (PVP), 899 Practical efficacy, 36
814 Pomalidomide Prader-Willi syndrome, 671
Podofilox, 1083 immunosuppressive uses of, 988 Pralatrexate, 958t, 958–959
Podophyllum resin, 1083 multiple myeloma treated with, 971 Pralidoxime (PAM), 132, 135t
Poisoned patient management, 1035–1046. Ponatinib, 967 Pramipexole. See also Dopamine receptor
See also Toxicology; specific Pontocaine, 460f agonists
poisons Poor metabolizer (PM), 67, 75t Parkinson’s disease treated with, 498, 508t
epidemiology of, 1035 Pork tapeworms restless legs syndrome treated with, 507,
initial, 1037–1040 niclosamide for, 943 508t
antidotes, specific, 1040, 1041t praziquantel for, 944–945 Pramlintide, 764, 769t
decontamination, 1039–1040 Portable pen injectors, insulin, 756 Pramoxine, 1084
ECG and imaging, 1038–1039, 1039f Portal hypertension, 1114 Pranlukast, 332
elimination enhancement Posaconazole, 858t, 859, 861t Prasugrel, 620
dialysis, 1039t, 1040 Positive allosteric modulators, 24 Pravastatin, 632–634, 639t
forced diuresis, 1040 Positive chronotropic effect, 145 Praziquantel, 939t, 944–945
urinary pH manipulation, 1040 Positive dromotropic effect, 147 Prazosin, 159, 159t, 170t, 191t. See also
history and physical examination, Positive inotropic effect, 147 Adrenoceptor antagonist drugs
1037–1038 Postantibiotic effect (PAE), 828, 910t, hypertension treated with, 179t, 184
laboratory, 1038t, 1038–1039 910–911 structure of, 157f
toxicology screening tests, 1039, Postantibiotic leukocyte enhancement Precision medicine, 38, 74
1039t (PALE), 911 Preclinical safety and toxicity testing, 13, 13t
mechanisms of death in, 1036–1037 Postcoital contraceptives, 736t, 736–737 Precocious puberty, central, 678
toxicodynamics of, 1036 Posterior pituitary hormones, 680–682, Prednisolone, 709t. See also Corticosteroids
toxicokinetics of 684t, 685t structure of, 706f
clearance, 1035–1036 Postmenopausal hormonal therapy, 725–726 topical, 1079–1081, 1080t, 1081t
volume of distribution, 1035 Postoperative nausea and vomiting, Prednisone, 709t. See also Corticosteroids
toxic syndromes, 1040–1046 1104–1105, 1116t, 1117t asthma treated with, 355, 362t
Poison ivy, 983 Postpartum hemorrhage, ergot alkaloids delayed-release, 658
Poisons, 3, 1035. See also Toxicology for, 295 topical, 1079–1081, 1080t, 1081t
Poke root, 1133t Postsynaptic regulation, autonomic, 103, 103f Pregabalin
Poliovirus vaccine, inactivated (IPV), 1177t Posttetanic facilitation, 481 analgesic uses of, 560b
Polybrominated biphenyl ethers (PBDEs), Post-traumatic stress disorder (PTSD), 533, restless legs syndrome treated with, 507
1015 536, 544 seizures treated with, 420, 436t
Polybrominated biphenyls (PBBs), 1015 Postural baroreflex, 175, 175f Preganglionic parasympathetic fibers, 91
Polycarbophil, 1098 Potassium, arrhythmia treated with, 248, Pregnancy
Polychlorinated biphenyls (PCBs), 1006b, 251t hypothyroidism and, 697
1014–1016 Potassium channels, 229 lithium in, 527
Polychlorinated dibenzofurans (PCDFs), Potassium iodide, 695, 701t multiple pregnancies in, 676
+
1015 Potassium ion (K ) pharmacology in, 1047–1057
Polychlorinated dibenzo-p-dioxins on conductance, 231b lactation pharmacology in, 1055t,
(PCDDs, dioxins), 1015 effects of, 231b 1055–1056
Polycystic kidney disease, autosomal on electrochemical gradient, 231b pharmacodynamics of, 1048–1050
dominant, 268 in membrane electrical activity, pharmacokinetics of, 1047–1048
Polyene macrolides, 853–854, 861t. See also 229–230, 230f teratogens, 1049f, 1049–1050, 1051t,
specific types Potassium perchlorate, 695 1052t
Polyethylene glycol-electrolyte solution, for Potassium-sparing diuretics, 177, 265f, toxic drug actions in fetus in, 1049
toxin elimination, 1040 265–267, 266t, 273t sedative-hypnotic drugs in, 383
Polyethylene glycol (PEG), balanced, 1099 combinations thyrotoxicosis in, 700